Tuesday, November 17, 2015 6:30:46 PM
2014
December – Dosed first cancer patient with entolimod in Russian Federation
October – Opened IND for entolimod in the Russian Federation
October – Dosed first healthy subject with CBLB612 in Russian Federation
September – Achieved agreement with FDA that existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization (pre-EUA) submission for entolimod’s biodefense indication
September – Completed enrollment of Phase 1 advanced cancer trial with entolimod at Roswell Park Cancer Institute
August – Opened IND for CBLB612 in the Russian Federation
April – Reported Phase 1 trial for CBL0102 (predecessor to CBL0137)
http://www.cbiolabs.com/history
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM